Lenvima (Lenvatinib)

lenvatinib 4 mg capsule, 30 · ORAL · PBS code 13252L

STREAMLINED

What it costs

AU$2000 PBS-determined price per 60 units

Most patients pay only the standard PBS co-payment, not the full price above — up to AU$25.00 per script (general) or AU$7.70 (concession/Safety Net) in 2026. The figure above is what the PBS pays the pharmacy; the Australian Government subsidises the rest. Always confirm the current amount with your pharmacist.

• First listed on the PBS: 2023-05-01.
• Repeats: 2.
• PBS program: GE.

Eligibility criteria for subsidised access

The following is the government's own wording from the PBS Schedule, shown unchanged.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Stage IV clear cell variant renal cell carcinoma (RCC)

Initial treatment

Patient must have a prognostic International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) survival risk classification score at treatment initiation with this drug and pembrolizumab of either: (i) 1 to 2 (intermediate risk), (ii) 3 to 6 (poor risk); document the IMDC risk classification score in the patient's medical records; AND

The condition must be untreated; AND

Patient must have a WHO performance status of 2 or less; AND

Patient must be undergoing combination therapy consisting of: (i) pembrolizumab, (ii) lenvatinib; or

Patient must be undergoing monotherapy with this drug due to a contraindication/intolerance to the other drug in the combination mentioned above, requiring temporary/permanent discontinuation; document the details in the patient's medical records; AND

Must be treated by a medical practitioner.

Listing of Pharmaceutical Benefits (NHL) - Schedule 4 part 1

Stage IV clear cell variant renal cell carcinoma (RCC)

Continuing treatment

Patient must have previously received PBS-subsidised treatment with this drug for this condition; AND

Patient must not have developed disease progression while receiving treatment with this drug for this condition; AND

Patient must be undergoing combination therapy consisting of: (i) pembrolizumab, (ii) lenvatinib; or

Patient must be undergoing monotherapy with this drug after completing an equivalent of 24 cumulative months of pembrolizumab treatment, measured from the first administered dose; AND

Must be treated by a medical practitioner; or

Must be treated by a nurse practitioner where both of the following are occurring: (i) patient care is being shared with a medical practitioner, (ii) the prescription continues existing therapy with this medicine.

In a patient who has experienced an intolerance to pembrolizumab, details of intolerance must be documented in the patient's medical record.

Sponsor: Eisai Australia Pty Ltd ABN 73 117 970 993

Not medical advice. Voxsanity republishes public PBS data in plain English. PBS listing status and criteria can change; always confirm current subsidised availability with your doctor or pharmacist.

Source: Pharmaceutical Benefits Scheme (PBS), © Commonwealth of Australia. Data used and redistributed under permission; not modified from its original wording where displayed verbatim.